NEWS
Cancer Network | OQ011 Yields Positive Safety and Efficacy in Treating Hand-Foot Skin Reaction–Related Pain

OQ011, a topical ointment for hand-foot skin reaction-related pain, yielded positive safety and efficacy in part 1 of 2 phase 2 NOVA-II trial. Investigators reported that treatment with OQ011 yielded positive patient-reported outcomes in hand-foot skin reaction (HFSR)–related pain associated with VEGFR inhibitor-based therapies, according to findings from part 1 of the phase 2 NOVA-II […]

Empowered Patient Radio | Administering Fibroblasts to Regenerate Tissue in Treatment of Degenerative Disc Disease and MS with Hamid Khoja FibroBiologics

Hamid Khoja is the Chief Scientific Officer of FibroBiologics which is developing regenerative medicine using fibroblasts which are one of the most abundant cells in the human body. While stem cell therapy has gotten significant attention, fibroblasts are easier to source and grow. Hamid elaborates, “Just to give you a sense of some of the capabilities […]

BioSpace | Clinical Catch-Up: Veru, Pfizer, Regeneron and More

Although things appeared to quiet down for COVID-19-related clinical trial news, there were plenty of announcements for other indications. Here’s a look. COVID-19-Related Veru reported the Independent Data Monitoring Committee (IDMC) planned a conditional power analysis of the first 75 patients in its Phase III COVID-19 registration trial of sabizabulin. The trial studied the drug’s effects in […]